HB Wealth Management LLC Has $10.18 Million Stock Position in Danaher Corporation $DHR

HB Wealth Management LLC reduced its holdings in shares of Danaher Corporation (NYSE:DHR) by 9.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,535 shares of the conglomerate’s stock after selling 5,409 shares during the quarter. HB Wealth Management LLC’s holdings in Danaher were worth $10,180,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Hills Bank & Trust Co boosted its holdings in Danaher by 0.3% during the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock worth $3,693,000 after purchasing an additional 53 shares during the last quarter. Worth Financial Advisory Group LLC boosted its holdings in Danaher by 4.6% during the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after purchasing an additional 53 shares during the last quarter. Sageworth Trust Co boosted its holdings in Danaher by 2.3% during the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock worth $493,000 after purchasing an additional 54 shares during the last quarter. 1834 Investment Advisors Co. boosted its holdings in Danaher by 3.3% during the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 54 shares during the last quarter. Finally, Bruce G. Allen Investments LLC boosted its holdings in Danaher by 13.1% during the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after purchasing an additional 54 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

NYSE DHR opened at $198.05 on Wednesday. The company’s 50 day moving average is $199.55 and its 200-day moving average is $197.31. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.41. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The firm has a market cap of $141.82 billion, a P/E ratio of 42.14, a price-to-earnings-growth ratio of 2.65 and a beta of 0.75.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter in the previous year, the firm posted $1.72 earnings per share. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s payout ratio is 27.23%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several analyst reports. Barclays restated an “overweight” rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Wells Fargo & Company cut their price target on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Evercore ISI lowered their price objective on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Finally, Robert W. Baird lifted their price objective on shares of Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research report on Friday, July 18th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $245.91.

Insiders Place Their Bets

In related news, Director Teri List sold 2,778 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 11.20% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.